General and administrative expenses for the nine months fell USD 5.1 million from the prior-year period, mainly on lower equity-based compensation of USD 4.8 million, legal costs of USD 0.5 million and professional fees of USD 0.4 million, partly offset by higher personnel costs …
Management said revenue reached a record USD 146.3 million, up 14.9% from a year earlier, entirely organic and ahead of its outlook of at least USD 145.7 million. At constant currency, revenue grew 11.2%. For the first nine months, revenue reached USD 425.7 million, …
The filing states revenue increased USD 376,000, or 130%, from the third quarter of 2025, primarily due to increased sales of products to corporate customers and products used in residential installations. The net loss was approximately USD 2.3 million, a decrease of approximately USD …
Following the November 2025 sale of its Nestor cables business, results for fiscal 2026 and prior periods present the Clearfield segment as continuing operations, with Nestor in discontinued operations.
Research and development expenses were approximately USD 5.4 million for the quarter, compared with USD 2.5 million a year earlier, and USD 13.0 million for the nine months, against USD 8.3 million. General and administrative expense was about USD 2.7 million, up from USD …
For the nine months, net loss was USD 30.86 million, or USD 0.32 per share, against USD 23.10 million, or USD 0.24 per share. Weighted average shares outstanding were about 95.2 million.
Cash, cash equivalents and marketable securities were USD 430.2 million as of September 30, compared with USD 457.5 million at June 30. The company continues to guide that its cash funds operations into 2029.
Net loss was USD 10.6 million for the quarter against USD 2.1 million a year earlier, and USD 24.5 million for the nine months against USD 15.5 million. The prior-year quarter included USD 3.3 million of license revenue recognized on FDA acceptance of the …
Net income for the quarter was USD 77.8 million. It included the gain on divestiture of assets associated with the transaction, whose revenues and expenses continued to be classified as discontinued operations, along with ongoingResearch and DevelopmentInvestmentsupported by the remaining general and administrative expenses.
Research and development expense was USD 34.2 million, up USD 13.4 million, or 64%. Upfront payments and clinical milestones under the license agreement with CSPC accounted for USD 15.0 million ofResearch and Developmentexpense in the quarter and USD 25.0 million for the nine months. …